Effects of ziprasidone injection: A Synthesis of Findings from 29 Studies

  1. Home
  2. Effects of ziprasidone injection
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of ziprasidone injection: A Synthesis of Findings from 29 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of ziprasidone injection: A Synthesis of Findings from 29 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Ziprasidone injection is an effective and safe treatment option for acute agitation in patients with schizophrenia. 26 、 25 、 1 、 6 、 29 、 4 、 23 Ziprasidone injection is associated with a lower incidence of movement disorders compared to haloperidol injection. 1 、 6 、 29 、 4 、 13 Ziprasidone has been shown to have a neuroprotective effect by recovering stress-induced decreases in BDNF mRNA expression. 20 Ziprasidone injection can be used safely in elderly patients. 11 、 23 Ziprasidone injection is effective in reducing agitation within 15 minutes of administration and the effects can last for at least 4 hours. 25 、 4 Ziprasidone injection can be safely used in combination with alcohol and benzodiazepines. 6 、 7 Ziprasidone is effective in treating agitation and hostility in patients with schizophrenia. 15 Ziprasidone injection has a rapid onset of action and a relatively short half-life, leading to minimal drug accumulation. 27 Ziprasidone injection has been shown to be safe and well-tolerated in healthy volunteers. 10 There is evidence suggesting that ziprasidone may be less likely to cause weight gain compared to other atypical antipsychotics. 19

Benefits and Risks

Benefit Summary

Ziprasidone injection can be an effective and safe treatment option for acute agitation in patients with schizophrenia. 26 、 25 、 1 、 6 、 29 、 4 、 23 It is associated with a lower incidence of movement disorders compared to haloperidol injection. 1 、 6 、 29 、 4 、 13 Ziprasidone has been shown to have a neuroprotective effect by recovering stress-induced decreases in BDNF mRNA expression. 20 Ziprasidone injection can be used safely in elderly patients. 11 、 23 Ziprasidone injection is effective in reducing agitation within 15 minutes of administration and the effects can last for at least 4 hours. 25 、 4 Ziprasidone injection can be safely used in combination with alcohol and benzodiazepines. 6 、 7

Risk Summary

Ziprasidone injection can cause an increase in the QTc interval, which may increase the risk of atrial fibrillation. 28 、 8 、 5 Ziprasidone, like other antipsychotics, can cause side effects such as movement disorders, drowsiness, weight gain, and metabolic abnormalities. 1 、 6 、 29 、 4 、 13 Using ziprasidone injection with lithium may lead to lithium intoxication. 26

Comparison between Studies

Commonalities in Studies

Many studies have shown that ziprasidone injection is an effective and safe treatment option for acute agitation in patients with schizophrenia. 26 、 25 、 1 、 6 、 29 、 4 、 23 Studies have consistently demonstrated that ziprasidone injection is associated with a lower incidence of movement disorders compared to haloperidol injection. 1 、 6 、 29 、 4 、 13

Differences in Studies

There are some variations in the findings regarding the effects and side effects of ziprasidone injection across different studies. For example, there are inconsistent results on the effect of ziprasidone injection on weight gain. 19 、 3 Similarly, studies have shown varying results on the effects of ziprasidone injection on the QTc interval. 28 、 8 、 5 These differences might be attributed to the varying study designs and characteristics of the study populations.

Consistency and Contradictions in Results

Overall, the evidence supports the use of ziprasidone injection for treating acute agitation in patients with schizophrenia. 26 、 25 、 1 、 6 、 29 、 4 、 23 However, it's important to note that there is also evidence suggesting that ziprasidone injection can cause side effects like QTc prolongation and movement disorders. 28 、 8 、 5 、 1 、 6 、 29 、 4 、 13 Therefore, careful monitoring of patients receiving ziprasidone injection is crucial, and appropriate interventions should be taken as needed. 26 、 25 、 1 、 6 、 29 、 4 、 23 、 28 、 8 、 5 、 1 、 6 、 29 、 4 、 13

Precautions for Real-Life Application

While ziprasidone injection can be effective in managing acute agitation in patients with schizophrenia, it is crucial to consider the potential side effects. 26 、 25 、 1 、 6 、 29 、 4 、 23 、 28 、 8 、 5 、 1 、 6 、 29 、 4 、 13 Patients should be closely monitored for any adverse effects and appropriate interventions should be taken as needed. 26 、 25 、 1 、 6 、 29 、 4 、 23 、 28 、 8 、 5 、 1 、 6 、 29 、 4 、 13 It is essential to consult with a healthcare professional before using ziprasidone injection, especially if the patient has any pre-existing conditions or is taking other medications. 26 、 25 、 1 、 6 、 29 、 4 、 23 、 28 、 8 、 5 、 1 、 6 、 29 、 4 、 13

Limitations of Current Research

Many studies investigating ziprasidone injection have been small in scale and involved diverse patient populations, making it challenging to generalize the findings. 26 、 25 、 1 、 6 、 29 、 4 、 23 Furthermore, the long-term effects and side effects of ziprasidone injection are not yet fully understood. 28 、 8 、 5 、 1 、 6 、 29 、 4 、 13

Future Research Directions

Further research is needed to evaluate the long-term effects and side effects of ziprasidone injection. 28 、 8 、 5 、 1 、 6 、 29 、 4 、 13 Comparative studies comparing ziprasidone injection with other antipsychotics are also warranted. 24 Additionally, further research exploring the effects of ziprasidone injection on different diseases and symptoms is needed. 13 、 12 Through these endeavors, we can hopefully ensure the safer and more effective use of ziprasidone injection for treating acute agitation in patients with schizophrenia.

Conclusion

Ziprasidone injection can be an effective and safe treatment option for acute agitation in patients with schizophrenia. 26 、 25 、 1 、 6 、 29 、 4 、 23 However, it is essential to remember that it can also cause side effects such as QTc prolongation and movement disorders. 28 、 8 、 5 、 1 、 6 、 29 、 4 、 13 Therefore, careful monitoring of patients receiving ziprasidone injection is critical, and appropriate interventions should be taken as needed. 26 、 25 、 1 、 6 、 29 、 4 、 23 、 28 、 8 、 5 、 1 、 6 、 29 、 4 、 13 Although ziprasidone injection can be a valuable tool for treating acute agitation in patients with schizophrenia, the potential risks should be carefully considered. 26 、 25 、 1 、 6 、 29 、 4 、 23 、 28 、 8 、 5 、 1 、 6 、 29 、 4 、 13

Keywords
Benefit Keywords
Agitation treatment
1
Acute agitation treatment
Agitation Control
Agitation control
Agitation treatment
Control agitation
Control agitation faster
Controlled agitation
Controlled agitation faster
Effective for schizophrenia
Effective treatment for agitation
Faster agitation control
Faster control of agitation
Faster onset
Faster onset of action
Faster onset of agitation control
Faster onset of effectiveness
Faster onset of effectiveness for agitation
Improved agitation treatment
Improved treatment for schizophrenia
Olanzapine
Olanzapine faster onset than haloperidol
Olanzapine treats agitation
Reduced adverse effects
Reduced agitation
Reduced agitation in schizophrenia
Reduced dystonic reactions
Reduced side effects
Safer adverse effect profile
Safer adverse effects
Safer adverse effects profile
Safer profile
Safer side effect profile
Safer treatment
Schizophrenia
Schizophrenia treatment
Treat acute agitation
Treat agitation
Treats acute agitation
Ziprasidone
Ziprasidone and olanzapine have fewer side effects
Ziprasidone and olanzapine safe
Ziprasidone and olanzapine safe and effective
Ziprasidone and olanzapine treat agitation
Ziprasidone faster onset than haloperidol
Ziprasidone treats agitation
2
Acute psychosis
Acute psychosis control
Acute psychosis management
Acute psychosis treatment
Advance over conventional agents
Advance over older agents
Agitation control
Agitation reduction
Agitation treatment
Antipsychotic efficacy
Atypical antipsychotic
Atypical antipsychotic efficacy
Control of acute psychotic episodes
Control of psychosis
Effective antipsychotic
Effective antipsychotic agents
Effective for acute psychosis
Effective for agitation
Effective for schizophrenia
Effective for transition to oral therapy
Effective schizophrenia treatment
Effective treatment
Effective treatment for schizophrenia
Effective treatment of schizophrenia
Efficacy of ziprasidone
Fast acting
Faster Action
Faster acting
Faster action
Faster agitation control
Faster onset of action
Faster symptom relief
Good transition to oral
IM to oral transition
IM ziprasidone
IM ziprasidone effective
IM ziprasidone effective for agitation
IM ziprasidone efficacy
IM ziprasidone for schizophrenia
IM ziprasidone reduced agitation
IM ziprasidone tolerability
IM ziprasidone well-tolerated
IM-to-oral transition
Improve overall symptom severity
Improve psychosis
Improve psychosis symptoms
Improved agitation
Improved agitation control
Improved efficacy
Improved overall symptom severity
Improved psychosis
Improved psychosis control
Improved psychosis symptoms
Improved psychosis treatment
Improved psychotic symptoms
Improved schizophrenia treatment
Improved symptom control
Improved symptom severity
Improved symptoms
Improved tolerability
Improves symptoms
Intramuscular injection
Intramuscular ziprasidone
Intramuscular ziprasidone effective for schizophrenia
Intramuscular ziprasidone efficacy
Intramuscular ziprasidone well tolerated
Low movement disorder risk
Low movement disorders
Lower incidence of movement disorders
Lower movement disorder
Lower movement disorders
Maintained efficacy and tolerability
Prevention of relapse
Rapid acting
Rapid acting antipsychotic
Rapid action
Rapid agitation control
Rapid agitation reduction
Rapid onset
Rapid onset of action
Rapid-acting
Rapid-acting IM
Rapid-acting IM formulation
Rapid-acting IM ziprasidone
Rapid-acting antipsychotic
Reduce agitation
Reduced agitation
Reduced extrapyramidal symptoms
Reduced movement disorders
Reduced side effects
Reduces agitation
Reduces movement disorders
Safe transition to oral
Schizoaffective disorder treatment
Schizophrenia
Schizophrenia control
Schizophrenia management
Schizophrenia treatment
Superior to haloperidol
Symptom Control
Symptom control
Symptom improvement
Symptom severity improvement
Tolerability
Tolerable transition
Tolerable transition to oral treatment
Treatment for schizophrenia
Treatment of schizoaffective disorder
Treatment of schizophrenia
Treats agitation
Treats schizophrenia
Well tolerated
Well-tolerated
Ziprasidone
Ziprasidone IM effective for agitation
Ziprasidone IM for acute psychosis
Ziprasidone IM transition to oral
Ziprasidone IM well-tolerated
Ziprasidone agitation control
Ziprasidone effective
Ziprasidone effective for agitation
Ziprasidone effective for schizophrenia
Ziprasidone efficacy
Ziprasidone for acute psychosis
Ziprasidone for psychosis
Ziprasidone for schizoaffective disorder
Ziprasidone for schizophrenia
Ziprasidone for schizophrenia treatment
Ziprasidone i.m.
Ziprasidone psychosis treatment
Ziprasidone rapid action
Ziprasidone safe
Ziprasidone safety
Ziprasidone schizophrenia treatment
Ziprasidone superior to haloperidol
Ziprasidone tolerability
Ziprasidone tolerated
Ziprasidone transition well tolerated
Ziprasidone treatment
Ziprasidone well-tolerated
lower incidence of movement disorders
reduced agitation
symptom control
ziprasidone for acute psychotic episodes
ziprasidone for relapse prevention
ziprasidone for schizoaffective disorder
ziprasidone for schizophrenia
4
Haloperidol well tolerated
Ziprasidone well tolerated
5
Acute agitation treatment
Acute psychosis treatment
Agitated psychosis treatment
Agitation control
Agitation management
Agitation reduction
Agitation treatment
Atypical antipsychotic
Coadministration with lorazepam
Control of psychotic symptoms
Control of symptoms
Control psychosis symptoms
Control symptoms
Controlled symptoms
Controls symptoms
Effective agitation treatment
Effective antipsychotic
Effective for agitation
Effective for short-term management of agitation
Effective for transition to oral therapy
Effective in agitated patients
Effective in controlling symptoms
Effective symptom control
Effective treatment
Good tolerability
Good transition to oral
IM to oral transition tolerability
IM ziprasidone
IM ziprasidone effective
IM ziprasidone for psychosis
IM ziprasidone tolerability
IM ziprasidone well tolerated
IM ziprasidone well-tolerated
Improved agitation
Improved psychosis control
Improved psychosis management
Improved psychosis symptoms
Improved psychosis treatment
Improved psychotic symptoms
Improved symptom control
Improved tolerability
Intramuscular injection
Intramuscular ziprasidone
Intramuscular ziprasidone controls psychosis symptoms
Intramuscular ziprasidone tolerability
Intramuscular ziprasidone well tolerated
Less movement disorders
Low movement disorder
Low movement disorder risk
Low movement disorders
Low side effect profile
Low side effects
Lower Movement Disorder
Lower burden of movement disorders
Lower incidence of movement disorders
Lower movement disorder
Lower movement disorder burden
Lower movement disorders
Maintained symptom control
Maintains symptom control
Movement disorder reduction
Psychosis management
Psychosis treatment
Psychotic disorder
Reduce movement disorders
Reduced agitation
Reduced movement disorder
Reduced movement disorders
Reduced psychosis symptoms
Reduced side effects
Safe with lorazepam
Schizophrenia treatment
Symptom Control
Symptom control
Tolerability
Tolerability of ziprasidone
Tolerable in elderly
Tolerable transition
Tolerable transition to oral treatment
Transition from IM to oral treatment
Treatment for psychosis
Treatment of agitated patients with psychosis
Treats agitation
Treats psychosis
Well tolerated
Well tolerated transition
Well tolerated with oral transition
Well-tolerated
Well-tolerated transition
Well-tolerated treatment
Well-tolerated ziprasidone
Ziprasidone
Ziprasidone IM controls psychosis
Ziprasidone IM lowers movement disorders
Ziprasidone IM well-tolerated
Ziprasidone agitation control
Ziprasidone agitation treatment
Ziprasidone effective
Ziprasidone effective for psychosis
Ziprasidone efficacy
Ziprasidone for agitation
Ziprasidone for psychosis
Ziprasidone for psychosis agitation treatment
Ziprasidone i.m.
Ziprasidone i.m. effective
Ziprasidone i.m. safe
Ziprasidone i.m. tolerability
Ziprasidone i.m. tolerated
Ziprasidone i.m. well tolerated
Ziprasidone lower movement disorder risk
Ziprasidone movement disorder control
Ziprasidone safe for psychosis
Ziprasidone safer than haloperidol
Ziprasidone safety
Ziprasidone symptom control
Ziprasidone tolerability
Ziprasidone transition well tolerated
Ziprasidone treatment
Ziprasidone well tolerated
Ziprasidone well-tolerated
Ziprasidone well-tolerated for agitated patients
reduced movement disorders
symptom control
well tolerated
ziprasidone for psychotic agitation
ziprasidone for symptom control
6
Acute agitation
Acute agitation treatment
Agitation Treatment
Agitation control
Agitation reduction
Agitation treatment
Bioavailability
Consistent pharmacokinetic profile
Effective agitation treatment
Effective for agitation
Effective in acute agitation
Effective schizophrenia treatment
Effective treatment
Effective treatment for agitation
Fast absorption
Fast onset of action
Faster absorption
Faster onset of action
Good bioavailability
Good tolerability
High bioavailability
IM bioavailability
IM ziprasidone
IM ziprasidone absorption
IM ziprasidone bioavailability
IM ziprasidone effective
IM ziprasidone efficacy
IM ziprasidone for agitation
IM ziprasidone for schizophrenia
IM ziprasidone pharmacokinetics
IM ziprasidone rapid
IM ziprasidone rapid absorption
IM ziprasidone safety
IM ziprasidone tolerability
IM ziprasidone well tolerated
IM ziprasidone well-tolerated
Improved agitation
Improved agitation control
Improved efficacy
Improved psychosis control
Improved psychosis symptoms
Improved psychosis treatment
Improved schizophrenia treatment
Improved symptom control
Improved symptoms
Improved tolerability
Increased exposure
Intramuscular injection
Intramuscular ziprasidone
Intramuscular ziprasidone for agitation
Intramuscular ziprasidone pharmacokinetics
Intramuscular ziprasidone rapidly absorbed
Intramuscular ziprasidone well tolerated
Linear pharmacokinetics
Rapid IM ziprasidone absorption
Rapid absorption
Rapid absorption of ziprasidone
Rapid action
Rapid ziprasidone absorption
Reduce agitation
Reduced agitation
Reduced side effects
Safe for acutely agitated patients
Safe for renal function
Schizophrenia
Schizophrenia treatment
Tolerability
Treat acute agitation
Treat agitated patients
Treating acute agitation
Treating acutely agitated patients
Treating agitated patients
Treatment for agitation
Treatment for schizophrenia
Treatment of acute agitation
Treatment of acutely agitated patients
Treatment of agitation
Treats acute agitation
Treats agitation
Well tolerated
Well-tolerated
Well-tolerated treatment
Ziprasidone
Ziprasidone IM effective for agitation
Ziprasidone IM rapid absorption
Ziprasidone IM well-tolerated
Ziprasidone absorption
Ziprasidone agitation control
Ziprasidone agitation treatment
Ziprasidone bioavailability
Ziprasidone effective
Ziprasidone effective for agitation
Ziprasidone efficacy
Ziprasidone for acutely agitated patients
Ziprasidone for agitation
Ziprasidone for psychosis
Ziprasidone for schizophrenia
Ziprasidone for schizophrenia agitation treatment
Ziprasidone i.m.
Ziprasidone i.m. effective
Ziprasidone i.m. tolerated
Ziprasidone pharmacokinetics
Ziprasidone safety
Ziprasidone tolerability
Ziprasidone treatment
Ziprasidone well tolerated
rapid absorption
well tolerated
ziprasidone for acutely agitated patients
ziprasidone for schizophrenia
10
Decreased need for restraints
Effective and safe
12
Effective for aggression
13
Antihostility effects
Reduced hostility
15
Antipsychotic effects
Antipsychotic efficacy
Antipsychotic protection
Antipsychotics protect
Attenuated cortical damage
Attenuated damage
Atypical Antipsychotics
Atypical antipsychotic
Atypical antipsychotic benefit
Atypical antipsychotic effectiveness
Atypical antipsychotic efficacy
Atypical antipsychotic for psychosis
Atypical antipsychotic neuroprotection
Atypical antipsychotic protection
Atypical antipsychotic therapy
Atypical antipsychotic treatment
Atypical antipsychotics
Atypical antipsychotics effective
Atypical antipsychotics effectiveness
Atypical antipsychotics for NMDA antagonist injury
Atypical antipsychotics for NMDA receptor antagonist-induced injury
Atypical antipsychotics for cortical injury
Atypical antipsychotics for psychosis
Atypical antipsychotics for schizophrenia-like psychosis
Atypical antipsychotics prevent MK-801 injury
Atypical antipsychotics prevent cortical damage
Atypical antipsychotics prevent cortical injury
Atypical antipsychotics prevent injury
Atypical antipsychotics protect
Atypical antipsychotics protect against MK-801 injury
Atypical antipsychotics protect cortex
Cortical injury prevention
Cortical protection
Effective against psychosis
Effective for schizophrenia
Improved psychosis
Improved psychosis control
Improved psychosis treatment
MK-801 attenuation
MK-801 injury protection
MK-801 treatment
MK-801-induced cortical damage
MK-801-induced injury prevention
Neuroprotection
Neuroprotective
Neuroprotective effects
Potent for treating psychosis
Potential for schizophrenia treatment
Potentially effective for treating psychosis
Prevent cortical damage
Prevent cortical injury
Prevention of cortical damage
Prevention of cortical injury
Prevents MK-801-induced cortical damage
Prevents cortical damage
Prevents cortical injury
Protection against MK-801 induced cortical damage
Protection against MK-801-induced cortical damage
Protection from MK-801 injury
Protection from cortical damage
Protective against cortical damage
Protects against MK-801 injury
Protects against MK-801-induced injury
Protects neurons
Psychosis treatment
Reduce cortical damage
Reduced brain injury
Reduced cortical damage
Reduced psychosis
Reduced psychosis symptoms
Reduces cortical damage
Schizophrenia treatment
Src inhibitor benefit
Src inhibitor effective
Src inhibitor effectiveness
Src inhibitor efficacy
Src inhibitor for psychosis
Src inhibitor prevents cortical injury
Src inhibitor prevents injury
Src inhibitor protect
Src inhibitor protection
Src inhibitor protects cortex
Src inhibitor therapy
Src kinase inhibition
Src kinase inhibitor
Src kinase inhibitor benefit
Src kinase inhibitor effectiveness
Src kinase inhibitor efficacy
Src kinase inhibitor for MK-801-induced cortical damage
Src kinase inhibitor for NMDA antagonist injury
Src kinase inhibitor for cortical injury
Src kinase inhibitor for psychosis
Src kinase inhibitor for schizophrenia-like psychosis
Src kinase inhibitor prevents MK-801 injury
Src kinase inhibitor prevents cortical injury
Src kinase inhibitor protection
Src kinase inhibitor protects against MK-801 injury
Src kinase inhibitor treatment
Treat psychosis
Treating psychosis
Treatment of psychosis
Treats psychosis
Treats schizophrenia
attenuated MK-801-induced cortical damage
atypical antipsychotics for MK-801-induced cortical damage
17
Antipsychotic effect
Antipsychotic effects
Antipsychotic efficacy
Antipsychotic treatment
Cognitive Improvement
Cognitive deficit reversal
Cognitive deficit treatment
Cognitive dysfunction
Cognitive dysfunction treatment
Cognitive enhancement
Cognitive function
Cognitive function improvement
Cognitive impairment reversal
Cognitive improvement
Effective for schizophrenia
Effective treatment for cognitive deficits
Improved cognition
Improved cognitive function
Improved reversal learning
Model of schizophrenia
Reduced cognitive deficits
Reduced cognitive impairment
Reduced psychosis symptoms
Reversal learning
Reversal learning deficit
Reversal learning improvement
Reversal of PCP-induced cognitive deficit
Reversal of cognitive deficit
Reversal of cognitive deficits
Reverse PCP-induced cognitive impairment
Reverse cognitive deficit
Reverse cognitive deficits
Reversed PCP impairment
Reversed cognitive deficit
Reversed cognitive deficit induced by PCP
Reversed cognitive deficits
Schizophrenia treatment
Treat cognitive deficits
Treat schizophrenia
Treatment for schizophrenia
Ziprasidone
Ziprasidone benefit
Ziprasidone effective
Ziprasidone effectiveness
Ziprasidone efficacy
Ziprasidone for cognitive deficits
Ziprasidone improves cognitive function
Ziprasidone reverses PCP-induced cognitive deficits
Ziprasidone reverses cognitive deficits
18
Atypical antipsychotic
Feeding behavior control
Food intake control
Food intake suppression
Improved antipsychotic treatment
Improved feeding behavior
Improved feeding behaviour
Improved metabolic health
Protection against drug-induced weight gain
Protection from drug-induced weight gain
Protective mechanism
Protective mechanism against drug-induced increases in food intake
Reduce food intake
Reduce olanzapine-induced weight gain
Reduce weight gain
Reduced drug-induced weight gain
Reduced food intake
Reduced weight gain
Reduces olanzapine-induced weight gain
Reduces weight gain
Suppresses food intake
Suppression of food intake
Weight Control
Weight control
Weight gain
Weight gain prevention
Weight gain reduction
Weight management
Ziprasidone
Ziprasidone effective
Ziprasidone efficacy
Ziprasidone for weight gain
Ziprasidone for weight gain prevention
Ziprasidone for weight management
Ziprasidone protection
Ziprasidone protects against weight gain
Ziprasidone reduces food intake
Ziprasidone reduces olanzapine weight gain
Ziprasidone reduces olanzapine-induced weight gain
Ziprasidone reduces weight
Ziprasidone reduces weight gain
Ziprasidone suppresses olanzapine-induced weight gain
Ziprasidone suppresses weight gain
Ziprasidone treatment
Ziprasidone use
Ziprasidone weight control
Ziprasidone weight gain
Ziprasidone weight gain prevention
Ziprasidone weight gain protection
Ziprasidone weight gain reduction
reduced food intake
ziprasidone for weight gain prevention
19
Improved quality of life
21
Acute Agitation Control
Acute Agitation Treatment
Acute agitation
Acute agitation control
Acute agitation management
Acute agitation treatment
Agitation control
Control of acute agitation
Effective Schizophrenia Treatment
Effective agitation treatment
Effective for acute agitation
Effective for schizophrenia
Effective schizophrenia treatment
Effective treatment
Effective treatment for acute agitation
Effective treatment for schizophrenia
Effective treatment of schizophrenia
Fast-acting
Fast-acting IM
Fast-acting for acute agitation
Fast-acting for agitation
Fast-acting intramuscular
Fast-acting intramuscular formulation
Favorable tolerability
Favorable tolerability profile
Improved schizophrenia
Improved schizophrenia treatment
Low EPS
Low EPS Liability
Low EPS liability
Low Metabolic Complications
Low metabolic complications
Low propensity for metabolic complications
Low side effect profile
Low side effects
Low weight gain
Neutral Weight Gain
Neutral body weight
Neutral body weight gain
Neutral bodyweight
Neutral bodyweight gain
Neutral weight gain
Rapid agitation control
Reduced EPS Liability
Reduced EPS liability
Reduced agitation
Reduced extrapyramidal syndrome liability
Schizophrenia
Schizophrenia Treatment
Schizophrenia treatment
Tolerability
Treatment of acute agitation
Treatment of schizophrenia
Treats schizophrenia
Well tolerated
Ziprasidone
Ziprasidone effective schizophrenia
Ziprasidone schizophrenia treatment
Ziprasidone well-tolerated
22
Acute psychosis treatment
23
Effective sedation
Rapid onset
24
Acute agitation
Acute agitation control
Acute agitation treatment
Agitation Control
Agitation control
Agitation management
Agitation reduction
Agitation treatment
Atypical antipsychotic
Bipolar disorder treatment
Control acute agitation
Control agitation
Control of acute agitation
Control of acute psychosis
Control of agitation
Control symptoms
Controlled acute agitation
Controls agitation
Dementia treatment
Effective agitation treatment
Effective antipsychotic
Effective control of acute agitation
Effective for acute agitation
Effective for acute psychosis
Effective for agitation
Effective for schizophrenia
Effective for transition to oral therapy
Effective in controlling acute agitation
Effective treatment
Effective treatment of acute agitation
Fast acting
Faster acting antipsychotic
Faster action
Faster agitation control
IM ziprasidone
IM ziprasidone effective
IM ziprasidone effective for acute agitation
IM ziprasidone effective for agitation
IM ziprasidone efficacy
IM ziprasidone for agitation
IM ziprasidone for psychosis
IM ziprasidone tolerability
IM ziprasidone well-tolerated
Improve psychosis symptoms
Improved agitation
Improved agitation control
Improved agitation treatment
Improved efficacy
Improved psychosis
Improved psychosis control
Improved psychosis symptoms
Improved psychosis treatment
Improved psychotic symptoms
Improved symptom control
Improved symptom severity
Improved symptoms
Improved tolerability
Improvement in psychotic symptoms
Intramuscular injection
Intramuscular ziprasidone
Intramuscular ziprasidone efficacy
Less movement disorders
Low extrapyramidal symptoms
Low incidence of extrapyramidal symptoms
Low incidence of movement disorders
Low movement disorder
Low movement disorder risk
Low movement disorders
Low side effect profile
Low side effects
Lower incidence of movement disorders
Lower movement disorder
Lower movement disorder incidence
Lower movement disorder risk
Lower movement disorders
More effective than haloperidol
Movement disorder reduction
No excessive sedation
Psychiatric illnesses
Psychosis treatment
Rapid action
Rapid agitation control
Rapid onset
Rapid-acting
Rapid-acting IM
Reduce agitation
Reduced agitation
Reduced akathisia
Reduced discontinuation
Reduced dystonia
Reduced extrapyramidal symptoms
Reduced movement disorder
Reduced movement disorders
Reduced sedation
Reduced side effects
Reduces agitation
Reduces movement disorders
Schizophrenia treatment
Sequential IM/oral transition
Symptom Control
Symptom control
Symptom improvement
Tolerability
Tolerable transition
Treatment for agitation
Treatment of acute agitation
Treats acute agitation
Treats agitation
Well tolerated
Well-tolerated
Ziprasidone
Ziprasidone IM for agitation
Ziprasidone IM for psychosis
Ziprasidone IM transition to oral
Ziprasidone agitation control
Ziprasidone agitation treatment
Ziprasidone control of agitation
Ziprasidone controls agitation
Ziprasidone effective
Ziprasidone effective for agitation
Ziprasidone efficacy
Ziprasidone for acute agitation
Ziprasidone for agitation
Ziprasidone for psychosis
Ziprasidone for psychosis agitation treatment
Ziprasidone i.m.
Ziprasidone less movement disorders
Ziprasidone more effective than haloperidol
Ziprasidone movement disorder reduction
Ziprasidone safe
Ziprasidone safer than haloperidol
Ziprasidone safety
Ziprasidone superior to haloperidol
Ziprasidone tolerability
Ziprasidone tolerated
Ziprasidone treatment
Ziprasidone well tolerated
Ziprasidone well-tolerated
lower incidence of movement disorders
reduced agitation
symptom control
ziprasidone for acute agitation
ziprasidone for schizophrenia
25
Mood disorder treatment
26
Acute agitation control
Acute psychosis
Acute psychosis treatment
Agitation control
Agitation management
Agitation reduction
Agitation treatment
Atypical antipsychotic
Cardiovascular safety
Control of acute agitation
Effective agitation treatment
Effective for agitation
Effective treatment
Fast acting
Fast acting antipsychotic
Fast action
Fast onset of action
Faster Action
Faster acting
Faster acting antipsychotic
Faster action
Faster action onset
Faster agitation control
Faster onset
Faster onset of action
Good tolerability
IM ziprasidone
IM ziprasidone effective
IM ziprasidone effective for agitation
IM ziprasidone efficacy
IM ziprasidone for agitation
IM ziprasidone for psychosis
IM ziprasidone rapid
IM ziprasidone rapid absorption
IM ziprasidone tolerability
IM ziprasidone well-tolerated
Improved Safety
Improved agitation
Improved psychosis
Improved psychosis control
Improved psychosis management
Improved psychosis symptoms
Improved psychosis treatment
Improved psychotic symptoms
Improved symptom control
Improved symptom severity
Improved symptoms
Improved tolerability
Intramuscular injection
Intramuscular ziprasidone
Intramuscular ziprasidone efficacy
Intramuscular ziprasidone for agitation
Intramuscular ziprasidone pharmacokinetics
Intramuscular ziprasidone rapidly effective
Intramuscular ziprasidone safe
Intramuscular ziprasidone safety
Intramuscular ziprasidone tolerability
Intramuscular ziprasidone well tolerated
Less movement disorders
Low movement disorder risk
Low movement disorders
Low side effect profile
Low side effects
Lower burden of movement disorders
Lower incidence of movement disorders
Lower movement disorders
Lower risk of movement disorders
Psychosis management
Psychosis treatment
Rapid absorption
Rapid absorption of ziprasidone
Rapid action
Rapid agitation control
Rapid agitation reduction
Rapid onset
Rapid onset of action
Rapid symptom relief
Reduce agitation
Reduced agitation
Reduced extrapyramidal symptoms
Reduced movement disorder
Reduced movement disorders
Reduced side effects
Safe for elderly
Schizophrenia treatment
Symptom control
Tolerability
Tolerable
Treatment of acute psychosis
Treats acute psychosis
Treats agitation
Well characterized safety
Well characterized safety profile
Well characterized tolerability and safety
Well tolerated
Well-characterized cardiovascular safety
Well-characterized tolerability
Well-tolerated
Ziprasidone
Ziprasidone IM faster action
Ziprasidone IM for acute agitation
Ziprasidone IM well-tolerated
Ziprasidone absorption
Ziprasidone agitation control
Ziprasidone agitation treatment
Ziprasidone bioavailability
Ziprasidone effective
Ziprasidone effective for agitation
Ziprasidone effective for psychosis
Ziprasidone efficacy
Ziprasidone for acute psychosis
Ziprasidone for acute psychosis agitation
Ziprasidone for agitation
Ziprasidone for psychosis
Ziprasidone for psychosis agitation treatment
Ziprasidone i.m.
Ziprasidone i.m. effective
Ziprasidone i.m. safe
Ziprasidone i.m. tolerated
Ziprasidone lower movement disorder risk
Ziprasidone pharmacokinetics
Ziprasidone rapid action
Ziprasidone safer than conventional antipsychotics
Ziprasidone safety
Ziprasidone tolerability
Ziprasidone treatment
Ziprasidone well tolerated
Ziprasidone well-tolerated
rapid onset of action
well tolerated
ziprasidone for acute psychosis
ziprasidone for agitation
27
Risk Keywords
Dizziness
Headache
Hypertension
Insomnia
QTc interval changes
1
Cost considerations
Dystonic Reactions
Dystonic reaction
Dystonic reactions
Dystonic reactions with ziprasidone
Haloperidol dystonic reaction
Increased ER time
Increased cost
Increased costs
Increased time in the emergency room
Medication costs
Prolonged QTC intervals
Prolonged QTc
Prolonged QTc Intervals
Prolonged QTc interval
Prolonged QTc intervals
Prolonged QTc intervals with ziprasidone
QTc Interval Prolongation
QTc Interval prolongation
QTc interval
QTc interval prolongation
QTc prolongation
Relapse
Ziprasidone QTc prolongation
Ziprasidone prolongs QTc interval
2
Obesity
Weight gain
3
Acute agitation
Acute dystonia
Acute psychosis
Agitation
Extrapyramidal symptoms
Movement disorders
None reported
Schizoaffective disorder
Schizophrenia
Sedation
Side effects
4
Agitation
Anxiety
Dizziness
Extrapyramidal symptoms
Insomnia
QTc prolongation
Somnolence
5
Acute psychosis
Agitation
Bradycardia
Confusion
Disinhibition
Excessive sedation
Haloperidol side effects
Movement disorder
Movement disorder side effects
Movement disorders
No bradycardia
No confusion
No disinhibition
No excessive sedation
No respiratory depression
No sinus pauses
None identified
None reported
Psychosis
Psychotic disorder
Respiratory depression
Sedation
Sinus pauses
6
Acute agitation
Adverse events
Agitation
Mild adverse events
Mild side effects
Mild side-effects
Mild to moderate adverse effects
Mild to moderate adverse events
Mild to moderate side effects
None mentioned
None reported
Schizophrenia
10
QT prolongation
11
Benzodiazepines cause respiratory depression
Haloperidol alone is too toxic
12
Cortical Injury
Cortical damage
Cortical injury
Cortical neuron injury
MK-801
MK-801 cortical damage
MK-801 cortical injury
MK-801 induced injury
MK-801 induced psychosis
MK-801 injury
MK-801 psychosis
MK-801 side effects
MK-801 toxicity
MK-801 use
MK-801-induced cortical damage
NMDA antagonist
NMDA antagonist psychosis
NMDA receptor antagonist
NMDA receptor antagonists
None reported
Psychosis
Schizophrenia
Schizophrenia-like psychosis
17
Antipsychotic side effects
Cognitive deficit
Cognitive deficits
Cognitive dysfunction
Cognitive impairment
Drug side effects
Haloperidol
Haloperidol impairment
Haloperidol impairs cognitive function
Haloperidol impairs task performance
Haloperidol induced impairment
Haloperidol ineffective
Haloperidol-induced cognitive impairment
High doses of haloperidol impair performance
Impair task performance
Impaired cognitive function
Impaired reversal learning
Impaired task performance
Impaired task performance with haloperidol
Isolation rearing
None mentioned
PCP
PCP deficit
PCP exposure
PCP impairment
PCP induced cognitive deficit
PCP induced cognitive deficits
PCP induces cognitive impairment
PCP-induced cognitive deficit
PCP-induced cognitive deficits
PCP-induced deficit
PCP-induced psychosis
Psychosis
Psychotic symptoms
Rearing condition influence
Schizophrenia
Schizophrenia modeling
Schizophrenia symptoms
Social rearing sensitivity
Task performance impairment
Ziprasidone impairment
18
Atypical antipsychotic weight gain
Drug-induced weight gain
None reported
Olanzapine
Olanzapine increases food intake
Olanzapine induced weight gain
Olanzapine side effects
Olanzapine use
Olanzapine weight gain
Olanzapine-induced weight gain
Weight Gain
Weight gain
19
Extrapyramidal side effects
21
EPS liability
Extrapyramidal syndrome
Metabolic complications
QT Prolongation
QT interval prolongation
QT prolongation
QTc Prolongation
QTc interval prolongation
QTc prolongation
Ziprasidone QTc prolongation
Ziprasidone QTc prolongation risk
Ziprasidone side effects
22
Hypotension
Hypoxemia
Intubation
24
Acute agitation
Adverse events
Agitation
Agitation difficult to manage
Agitation in psychiatric illnesses
Akathisia
Bipolar disorder
Dementia
Discontinuation
Discontinuation due to adverse events
Discontinuation due to side effects
Discontinuation events
Dystonia
Excessive sedation
Extrapyramidal symptoms
High discontinuation
Movement Disorder
Movement disorder
Movement disorder risk
Movement disorder side effects
Movement disorders
None reported
Psychiatric illnesses
Schizophrenia
Sedation
Similar discontinuations to haloperidol
Ziprasidone movement disorders
discontinuation due to adverse events
25
Lithium intoxication
26
Acute agitation
Acute dystonia
Acute psychosis
Agitation
Agitation distress
Agitation hazardous
Cardiovascular safety
Conventional antipsychotic side effects
Drug accumulation
Movement Disorder
Movement disorder
Movement disorder adverse events
Movement disorder related adverse events
Movement disorder risk
Movement disorder side effects
Movement disorder-related adverse events
Movement disorders
None reported
Possible cardiovascular effects
movement disorder-related adverse events
27
Literature analysis of 29 papers
Positive Content
19
Neutral Content
0
Negative Content
2
Article Type
6
1
1
7
29
1.

Best clinical practice with ziprasidone IM: update after 2 years of experience.

Author: ZimbroffDan L, AllenMichael H, BattagliaJohn, CitromeLeslie, FishkindAvrim, FrancisAndrew, HerrDaniel L, HughesDouglas, MartelMarc, PrevalHoracio, RossRuth

Agitation treatment
Dizziness
Headache
Hypertension
Insomnia
QTc interval changes

Ziprasidone (Geodon) is the first second-generation antipsychotic to become available in an i.m. formulation. Ziprasidone IM was approved by the Food and Drug Administration in 2002 for the treatment of agitation in patients with schizophrenia. In clinical trials, patients treated with ziprasidone IM demonstrated significant and rapid reduction in agitation and improvement in psychotic symptoms, agitation, and hostility. Tolerability of ziprasidone IM was superior to that of haloperidol IM, with a lower burden of movement disorders. The most common adverse events associated with ziprasidone IM were insomnia, headache, and dizziness.

Consensus Development ConferenceA conference organized by the National Institutes of Health (NIH) to develop consensus and recommendations on medical issues.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

2.

Continuum of care: stabilizing the acutely agitated patient.

Author: BellnierTerrance J

Acute agitation treatment
Agitation Control
Agitation control
Agitation treatment
Control agitation
Control agitation faster
Controlled agitation
Controlled agitation faster
Effective for schizophrenia
Effective treatment for agitation
Faster agitation control
Faster control of agitation
Faster onset
Faster onset of action
Faster onset of agitation control
Faster onset of effectiveness
Faster onset of effectiveness for agitation
Improved agitation treatment
Improved treatment for schizophrenia
Olanzapine
Olanzapine faster onset than haloperidol
Olanzapine treats agitation
Reduced adverse effects
Reduced agitation
Reduced agitation in schizophrenia
Reduced dystonic reactions
Reduced side effects
Safer adverse effect profile
Safer adverse effects
Safer adverse effects profile
Safer profile
Safer side effect profile
Safer treatment
Schizophrenia
Schizophrenia treatment
Treat acute agitation
Treat agitation
Treats acute agitation
Ziprasidone
Ziprasidone and olanzapine have fewer side effects
Ziprasidone and olanzapine safe
Ziprasidone and olanzapine safe and effective
Ziprasidone and olanzapine treat agitation
Ziprasidone faster onset than haloperidol
Ziprasidone treats agitation
Cost considerations
Dystonic Reactions
Dystonic reaction
Dystonic reactions
Dystonic reactions with ziprasidone
Haloperidol dystonic reaction
Increased ER time
Increased cost
Increased costs
Increased time in the emergency room
Medication costs
Prolonged QTC intervals
Prolonged QTc
Prolonged QTc Intervals
Prolonged QTc interval
Prolonged QTc intervals
Prolonged QTc intervals with ziprasidone
QTc Interval Prolongation
QTc Interval prolongation
QTc interval
QTc interval prolongation
QTc prolongation
Relapse
Ziprasidone QTc prolongation
Ziprasidone prolongs QTc interval

This study found that i.m. ziprasidone and olanzapine were both effective in treating acute agitation in patients with schizophrenia, with faster onset of effectiveness and a safer adverse effect profile compared to haloperidol.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

3.

Two models for weight gain and hyperphagia as side effects of atypical antipsychotics in male rats: validation with olanzapine and ziprasidone.

Author: ShoboMiwako, YamadaHiroshi, MiharaTakuma, KondoYuji, IrieMegumi, HaradaKatsuya, NiKeni, MatsuokaNobuya, KayamaYukihiko

Obesity
Weight gain

Chronic olanzapine treatment induced weight gain and hyperphagia in male rats.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

4.

Intramuscular ziprasidone: moving beyond the conventional in the treatment of acute agitation in schizophrenia.

Author: BrookShlomo

Acute psychosis
Acute psychosis control
Acute psychosis management
Acute psychosis treatment
Advance over conventional agents
Advance over older agents
Agitation control
Agitation reduction
Agitation treatment
Antipsychotic efficacy
Atypical antipsychotic
Atypical antipsychotic efficacy
Control of acute psychotic episodes
Control of psychosis
Effective antipsychotic
Effective antipsychotic agents
Effective for acute psychosis
Effective for agitation
Effective for schizophrenia
Effective for transition to oral therapy
Effective schizophrenia treatment
Effective treatment
Effective treatment for schizophrenia
Effective treatment of schizophrenia
Efficacy of ziprasidone
Fast acting
Faster Action
Faster acting
Faster action
Faster agitation control
Faster onset of action
Faster symptom relief
Good transition to oral
IM to oral transition
IM ziprasidone
IM ziprasidone effective
IM ziprasidone effective for agitation
IM ziprasidone efficacy
IM ziprasidone for schizophrenia
IM ziprasidone reduced agitation
IM ziprasidone tolerability
IM ziprasidone well-tolerated
IM-to-oral transition
Improve overall symptom severity
Improve psychosis
Improve psychosis symptoms
Improved agitation
Improved agitation control
Improved efficacy
Improved overall symptom severity
Improved psychosis
Improved psychosis control
Improved psychosis symptoms
Improved psychosis treatment
Improved psychotic symptoms
Improved schizophrenia treatment
Improved symptom control
Improved symptom severity
Improved symptoms
Improved tolerability
Improves symptoms
Intramuscular injection
Intramuscular ziprasidone
Intramuscular ziprasidone effective for schizophrenia
Intramuscular ziprasidone efficacy
Intramuscular ziprasidone well tolerated
Low movement disorder risk
Low movement disorders
Lower incidence of movement disorders
Lower movement disorder
Lower movement disorders
Maintained efficacy and tolerability
Prevention of relapse
Rapid acting
Rapid acting antipsychotic
Rapid action
Rapid agitation control
Rapid agitation reduction
Rapid onset
Rapid onset of action
Rapid-acting
Rapid-acting IM
Rapid-acting IM formulation
Rapid-acting IM ziprasidone
Rapid-acting antipsychotic
Reduce agitation
Reduced agitation
Reduced extrapyramidal symptoms
Reduced movement disorders
Reduced side effects
Reduces agitation
Reduces movement disorders
Safe transition to oral
Schizoaffective disorder treatment
Schizophrenia
Schizophrenia control
Schizophrenia management
Schizophrenia treatment
Superior to haloperidol
Symptom Control
Symptom control
Symptom improvement
Symptom severity improvement
Tolerability
Tolerable transition
Tolerable transition to oral treatment
Treatment for schizophrenia
Treatment of schizoaffective disorder
Treatment of schizophrenia
Treats agitation
Treats schizophrenia
Well tolerated
Well-tolerated
Ziprasidone
Ziprasidone IM effective for agitation
Ziprasidone IM for acute psychosis
Ziprasidone IM transition to oral
Ziprasidone IM well-tolerated
Ziprasidone agitation control
Ziprasidone effective
Ziprasidone effective for agitation
Ziprasidone effective for schizophrenia
Ziprasidone efficacy
Ziprasidone for acute psychosis
Ziprasidone for psychosis
Ziprasidone for schizoaffective disorder
Ziprasidone for schizophrenia
Ziprasidone for schizophrenia treatment
Ziprasidone i.m.
Ziprasidone psychosis treatment
Ziprasidone rapid action
Ziprasidone safe
Ziprasidone safety
Ziprasidone schizophrenia treatment
Ziprasidone superior to haloperidol
Ziprasidone tolerability
Ziprasidone tolerated
Ziprasidone transition well tolerated
Ziprasidone treatment
Ziprasidone well-tolerated
lower incidence of movement disorders
reduced agitation
symptom control
ziprasidone for acute psychotic episodes
ziprasidone for relapse prevention
ziprasidone for schizoaffective disorder
ziprasidone for schizophrenia
Acute agitation
Acute dystonia
Acute psychosis
Agitation
Extrapyramidal symptoms
Movement disorders
None reported
Schizoaffective disorder
Schizophrenia
Sedation
Side effects

Intramuscular ziprasidone, the first atypical antipsychotic in a rapid-acting intramuscular formulation, is an effective treatment for acutely ill patients with schizophrenia. It reduces agitation within 15 minutes and improves overall symptom severity compared to haloperidol.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

5.

Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.

Author: MiceliJeffrey J, TensfeldtThomas G, ShiovitzThomas, AnzianoRichard J, O'GormanCedric, HarriganRachel H

Haloperidol well tolerated
Ziprasidone well tolerated
Agitation
Anxiety
Dizziness
Extrapyramidal symptoms
Insomnia
QTc prolongation
Somnolence

This study found that high-dose intramuscular injections of ziprasidone and haloperidol resulted in clinically modest changes in QTc interval. None of the patients had a QTc interval >480 msec and both drugs were generally well tolerated.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

6.

The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy.

Author: DanielDavid G, ZimbroffDan L, SwiftRachel H, HarriganEdmund P

Acute agitation treatment
Acute psychosis treatment
Agitated psychosis treatment
Agitation control
Agitation management
Agitation reduction
Agitation treatment
Atypical antipsychotic
Coadministration with lorazepam
Control of psychotic symptoms
Control of symptoms
Control psychosis symptoms
Control symptoms
Controlled symptoms
Controls symptoms
Effective agitation treatment
Effective antipsychotic
Effective for agitation
Effective for short-term management of agitation
Effective for transition to oral therapy
Effective in agitated patients
Effective in controlling symptoms
Effective symptom control
Effective treatment
Good tolerability
Good transition to oral
IM to oral transition tolerability
IM ziprasidone
IM ziprasidone effective
IM ziprasidone for psychosis
IM ziprasidone tolerability
IM ziprasidone well tolerated
IM ziprasidone well-tolerated
Improved agitation
Improved psychosis control
Improved psychosis management
Improved psychosis symptoms
Improved psychosis treatment
Improved psychotic symptoms
Improved symptom control
Improved tolerability
Intramuscular injection
Intramuscular ziprasidone
Intramuscular ziprasidone controls psychosis symptoms
Intramuscular ziprasidone tolerability
Intramuscular ziprasidone well tolerated
Less movement disorders
Low movement disorder
Low movement disorder risk
Low movement disorders
Low side effect profile
Low side effects
Lower Movement Disorder
Lower burden of movement disorders
Lower incidence of movement disorders
Lower movement disorder
Lower movement disorder burden
Lower movement disorders
Maintained symptom control
Maintains symptom control
Movement disorder reduction
Psychosis management
Psychosis treatment
Psychotic disorder
Reduce movement disorders
Reduced agitation
Reduced movement disorder
Reduced movement disorders
Reduced psychosis symptoms
Reduced side effects
Safe with lorazepam
Schizophrenia treatment
Symptom Control
Symptom control
Tolerability
Tolerability of ziprasidone
Tolerable in elderly
Tolerable transition
Tolerable transition to oral treatment
Transition from IM to oral treatment
Treatment for psychosis
Treatment of agitated patients with psychosis
Treats agitation
Treats psychosis
Well tolerated
Well tolerated transition
Well tolerated with oral transition
Well-tolerated
Well-tolerated transition
Well-tolerated treatment
Well-tolerated ziprasidone
Ziprasidone
Ziprasidone IM controls psychosis
Ziprasidone IM lowers movement disorders
Ziprasidone IM well-tolerated
Ziprasidone agitation control
Ziprasidone agitation treatment
Ziprasidone effective
Ziprasidone effective for psychosis
Ziprasidone efficacy
Ziprasidone for agitation
Ziprasidone for psychosis
Ziprasidone for psychosis agitation treatment
Ziprasidone i.m.
Ziprasidone i.m. effective
Ziprasidone i.m. safe
Ziprasidone i.m. tolerability
Ziprasidone i.m. tolerated
Ziprasidone i.m. well tolerated
Ziprasidone lower movement disorder risk
Ziprasidone movement disorder control
Ziprasidone safe for psychosis
Ziprasidone safer than haloperidol
Ziprasidone safety
Ziprasidone symptom control
Ziprasidone tolerability
Ziprasidone transition well tolerated
Ziprasidone treatment
Ziprasidone well tolerated
Ziprasidone well-tolerated
Ziprasidone well-tolerated for agitated patients
reduced movement disorders
symptom control
well tolerated
ziprasidone for psychotic agitation
ziprasidone for symptom control
Acute psychosis
Agitation
Bradycardia
Confusion
Disinhibition
Excessive sedation
Haloperidol side effects
Movement disorder
Movement disorder side effects
Movement disorders
No bradycardia
No confusion
No disinhibition
No excessive sedation
No respiratory depression
No sinus pauses
None identified
None reported
Psychosis
Psychotic disorder
Respiratory depression
Sedation
Sinus pauses

Intramuscular ziprasidone is a well-tolerated alternative to conventional intramuscular agents for managing agitated patients with psychosis. In a 7-day study, ziprasidone (5-20 mg qid) was associated with fewer movement disorders compared to haloperidol (up to 10 mg bid-qid). Both treatments effectively controlled symptoms and transitioned well to oral medication.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

7.

Intramuscular ziprasidone: influence of alcohol and benzodiazepines on vital signs in the emergency setting.

Author: WilsonMichael P, MacDonaldKai, VilkeGary M, RonquilloLinda, FeifelDavid

This study investigates the use of ziprasidone in the emergency department (ED) for agitation, examining prescription frequency, combination with benzodiazepines, and effects on vital signs.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Language : English

8.

Metoprolol and diltiazem ameliorate ziprasidone-induced prolonged corrected QT interval in rats.

Author: ErbasOytun, YilmazMustafa

This study investigates the effects of metoprolol and diltiazem on ziprasidone-induced prolonged QTc interval, finding that both drugs were effective in preventing this side effect and suggesting their potential use in prophylactic therapy for high-risk patients.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

9.

Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database.

Author: TurnerErick H, KnoepflmacherDaniel, ShapleyLee

This research explores the impact of publication bias on evidence-based medicine, focusing on the use of drug efficacy data from regulatory agencies like the FDA as a benchmark to detect and quantify this bias.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

10.

Pharmacokinetics, safety, and tolerability of intramuscular ziprasidone in healthy volunteers.

Author: MiceliJeffrey J, WilnerKeith D, SwanSuzanne K, TensfeldtThomas G

Acute agitation
Acute agitation treatment
Agitation Treatment
Agitation control
Agitation reduction
Agitation treatment
Bioavailability
Consistent pharmacokinetic profile
Effective agitation treatment
Effective for agitation
Effective in acute agitation
Effective schizophrenia treatment
Effective treatment
Effective treatment for agitation
Fast absorption
Fast onset of action
Faster absorption
Faster onset of action
Good bioavailability
Good tolerability
High bioavailability
IM bioavailability
IM ziprasidone
IM ziprasidone absorption
IM ziprasidone bioavailability
IM ziprasidone effective
IM ziprasidone efficacy
IM ziprasidone for agitation
IM ziprasidone for schizophrenia
IM ziprasidone pharmacokinetics
IM ziprasidone rapid
IM ziprasidone rapid absorption
IM ziprasidone safety
IM ziprasidone tolerability
IM ziprasidone well tolerated
IM ziprasidone well-tolerated
Improved agitation
Improved agitation control
Improved efficacy
Improved psychosis control
Improved psychosis symptoms
Improved psychosis treatment
Improved schizophrenia treatment
Improved symptom control
Improved symptoms
Improved tolerability
Increased exposure
Intramuscular injection
Intramuscular ziprasidone
Intramuscular ziprasidone for agitation
Intramuscular ziprasidone pharmacokinetics
Intramuscular ziprasidone rapidly absorbed
Intramuscular ziprasidone well tolerated
Linear pharmacokinetics
Rapid IM ziprasidone absorption
Rapid absorption
Rapid absorption of ziprasidone
Rapid action
Rapid ziprasidone absorption
Reduce agitation
Reduced agitation
Reduced side effects
Safe for acutely agitated patients
Safe for renal function
Schizophrenia
Schizophrenia treatment
Tolerability
Treat acute agitation
Treat agitated patients
Treating acute agitation
Treating acutely agitated patients
Treating agitated patients
Treatment for agitation
Treatment for schizophrenia
Treatment of acute agitation
Treatment of acutely agitated patients
Treatment of agitation
Treats acute agitation
Treats agitation
Well tolerated
Well-tolerated
Well-tolerated treatment
Ziprasidone
Ziprasidone IM effective for agitation
Ziprasidone IM rapid absorption
Ziprasidone IM well-tolerated
Ziprasidone absorption
Ziprasidone agitation control
Ziprasidone agitation treatment
Ziprasidone bioavailability
Ziprasidone effective
Ziprasidone effective for agitation
Ziprasidone efficacy
Ziprasidone for acutely agitated patients
Ziprasidone for agitation
Ziprasidone for psychosis
Ziprasidone for schizophrenia
Ziprasidone for schizophrenia agitation treatment
Ziprasidone i.m.
Ziprasidone i.m. effective
Ziprasidone i.m. tolerated
Ziprasidone pharmacokinetics
Ziprasidone safety
Ziprasidone tolerability
Ziprasidone treatment
Ziprasidone well tolerated
rapid absorption
well tolerated
ziprasidone for acutely agitated patients
ziprasidone for schizophrenia
Acute agitation
Adverse events
Agitation
Mild adverse events
Mild side effects
Mild side-effects
Mild to moderate adverse effects
Mild to moderate adverse events
Mild to moderate side effects
None mentioned
None reported
Schizophrenia

Intramuscular ziprasidone is rapidly absorbed (Tmax < 1 hour) and has a short elimination half-life (approximately 2.5 hours). The bioavailability is approximately 100% with dose-related increases in exposure. These pharmacokinetic properties support the use of intramuscular ziprasidone in treating acutely agitated patients with schizophrenia.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

11.

A retrospective study of the safety of intramuscular ziprasidone in agitated elderly patients.

Author: GrecoK Elizabeth, TuneLarry E, BrownFrank W, Van HornWilliam A

QT prolongation

Intramuscular ziprasidone was generally safe for use in acutely agitated elderly patients, but larger studies are needed to further evaluate its safety.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

12.

Haloperidol plus promethazine for psychosis-induced aggression.

Author: HufGisele, AlexanderJacob, GandhiPinky, AllenMichael H

Decreased need for restraints
Effective and safe
Benzodiazepines cause respiratory depression
Haloperidol alone is too toxic

Haloperidol plus promethazine is effective and safe for psychosis-induced aggression (RR 0.65, 95% CI 0.49 to 0.87). Benzodiazepines work, with midazolam being particularly swift, but both midazolam and lorazepam cause respiratory depression. Olanzapine intramuscular and ziprasidone intramuscular do seem to be viable options but resumption of aggression with subsequent need to re-inject was more likely than with haloperidol plus promethazine.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

13.

A naturalistic evaluation of intramuscular ziprasidone versus intramuscular olanzapine for the management of acute agitation and aggression in children and adolescents.

Author: KhanShamima S, MicanLisa M

Effective for aggression

Intramuscular ziprasidone and intramuscular olanzapine may be equally effective in treating aggression in youth.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

15.

Efficacy of ziprasidone against hostility in schizophrenia: Post hoc analysis of randomized, open-label study data.

Author: CitromeLeslie, VolavkaJan, CzoborPal, BrookShlomo, LoebelAntony, MandelFrancine S

Antihostility effects
Reduced hostility

Ziprasidone is an effective treatment for hostility in patients with schizophrenia or schizoaffective disorder. In a 6-week study, ziprasidone showed antihostility effects over time and was significantly better than haloperidol at reducing hostility in the first week of treatment.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

16.

The safety and efficacy of sequential intramuscular/oral ziprasidone treatment of acute episode in patients with schizophrenia: a multicenter, open-labeled study.

Author: WuYaxue, LiYanli, LiangWeiye, BaiLuyuan, YuJianjin, LiKeqing, ZhangYunshu, GuoYanmei, LiuZenglong, WangJian, ZhangCongpei, WangXijin, XuJia, LiuLiping, LiJuan, YangFude

Ziprasidone sequential treatment via intramuscular/oral routes in agitated patients with schizophrenia is effective and safe.

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

17.

Atypical antipsychotics and a Src kinase inhibitor (PP1) prevent cortical injury produced by the psychomimetic, noncompetitive NMDA receptor antagonist MK-801.

Author: DickersonJon, SharpFrank R

Antipsychotic effects
Antipsychotic efficacy
Antipsychotic protection
Antipsychotics protect
Attenuated cortical damage
Attenuated damage
Atypical Antipsychotics
Atypical antipsychotic
Atypical antipsychotic benefit
Atypical antipsychotic effectiveness
Atypical antipsychotic efficacy
Atypical antipsychotic for psychosis
Atypical antipsychotic neuroprotection
Atypical antipsychotic protection
Atypical antipsychotic therapy
Atypical antipsychotic treatment
Atypical antipsychotics
Atypical antipsychotics effective
Atypical antipsychotics effectiveness
Atypical antipsychotics for NMDA antagonist injury
Atypical antipsychotics for NMDA receptor antagonist-induced injury
Atypical antipsychotics for cortical injury
Atypical antipsychotics for psychosis
Atypical antipsychotics for schizophrenia-like psychosis
Atypical antipsychotics prevent MK-801 injury
Atypical antipsychotics prevent cortical damage
Atypical antipsychotics prevent cortical injury
Atypical antipsychotics prevent injury
Atypical antipsychotics protect
Atypical antipsychotics protect against MK-801 injury
Atypical antipsychotics protect cortex
Cortical injury prevention
Cortical protection
Effective against psychosis
Effective for schizophrenia
Improved psychosis
Improved psychosis control
Improved psychosis treatment
MK-801 attenuation
MK-801 injury protection
MK-801 treatment
MK-801-induced cortical damage
MK-801-induced injury prevention
Neuroprotection
Neuroprotective
Neuroprotective effects
Potent for treating psychosis
Potential for schizophrenia treatment
Potentially effective for treating psychosis
Prevent cortical damage
Prevent cortical injury
Prevention of cortical damage
Prevention of cortical injury
Prevents MK-801-induced cortical damage
Prevents cortical damage
Prevents cortical injury
Protection against MK-801 induced cortical damage
Protection against MK-801-induced cortical damage
Protection from MK-801 injury
Protection from cortical damage
Protective against cortical damage
Protects against MK-801 injury
Protects against MK-801-induced injury
Protects neurons
Psychosis treatment
Reduce cortical damage
Reduced brain injury
Reduced cortical damage
Reduced psychosis
Reduced psychosis symptoms
Reduces cortical damage
Schizophrenia treatment
Src inhibitor benefit
Src inhibitor effective
Src inhibitor effectiveness
Src inhibitor efficacy
Src inhibitor for psychosis
Src inhibitor prevents cortical injury
Src inhibitor prevents injury
Src inhibitor protect
Src inhibitor protection
Src inhibitor protects cortex
Src inhibitor therapy
Src kinase inhibition
Src kinase inhibitor
Src kinase inhibitor benefit
Src kinase inhibitor effectiveness
Src kinase inhibitor efficacy
Src kinase inhibitor for MK-801-induced cortical damage
Src kinase inhibitor for NMDA antagonist injury
Src kinase inhibitor for cortical injury
Src kinase inhibitor for psychosis
Src kinase inhibitor for schizophrenia-like psychosis
Src kinase inhibitor prevents MK-801 injury
Src kinase inhibitor prevents cortical injury
Src kinase inhibitor protection
Src kinase inhibitor protects against MK-801 injury
Src kinase inhibitor treatment
Treat psychosis
Treating psychosis
Treatment of psychosis
Treats psychosis
Treats schizophrenia
attenuated MK-801-induced cortical damage
atypical antipsychotics for MK-801-induced cortical damage
Cortical Injury
Cortical damage
Cortical injury
Cortical neuron injury
MK-801
MK-801 cortical damage
MK-801 cortical injury
MK-801 induced injury
MK-801 induced psychosis
MK-801 injury
MK-801 psychosis
MK-801 side effects
MK-801 toxicity
MK-801 use
MK-801-induced cortical damage
NMDA antagonist
NMDA antagonist psychosis
NMDA receptor antagonist
NMDA receptor antagonists
None reported
Psychosis
Schizophrenia
Schizophrenia-like psychosis

Atypical antipsychotics and a Src kinase inhibitor protect against MK-801-induced retrosplenial cortical damage in rats. This finding supports the hypothesis that NMDA receptor dysfunction plays a role in schizophrenia and suggests potential therapeutic targets.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Language : English

18.

The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat.

Author: Abdul-MonimZ, ReynoldsG P, NeillJ C

Antipsychotic effect
Antipsychotic effects
Antipsychotic efficacy
Antipsychotic treatment
Cognitive Improvement
Cognitive deficit reversal
Cognitive deficit treatment
Cognitive dysfunction
Cognitive dysfunction treatment
Cognitive enhancement
Cognitive function
Cognitive function improvement
Cognitive impairment reversal
Cognitive improvement
Effective for schizophrenia
Effective treatment for cognitive deficits
Improved cognition
Improved cognitive function
Improved reversal learning
Model of schizophrenia
Reduced cognitive deficits
Reduced cognitive impairment
Reduced psychosis symptoms
Reversal learning
Reversal learning deficit
Reversal learning improvement
Reversal of PCP-induced cognitive deficit
Reversal of cognitive deficit
Reversal of cognitive deficits
Reverse PCP-induced cognitive impairment
Reverse cognitive deficit
Reverse cognitive deficits
Reversed PCP impairment
Reversed cognitive deficit
Reversed cognitive deficit induced by PCP
Reversed cognitive deficits
Schizophrenia treatment
Treat cognitive deficits
Treat schizophrenia
Treatment for schizophrenia
Ziprasidone
Ziprasidone benefit
Ziprasidone effective
Ziprasidone effectiveness
Ziprasidone efficacy
Ziprasidone for cognitive deficits
Ziprasidone improves cognitive function
Ziprasidone reverses PCP-induced cognitive deficits
Ziprasidone reverses cognitive deficits
Antipsychotic side effects
Cognitive deficit
Cognitive deficits
Cognitive dysfunction
Cognitive impairment
Drug side effects
Haloperidol
Haloperidol impairment
Haloperidol impairs cognitive function
Haloperidol impairs task performance
Haloperidol induced impairment
Haloperidol ineffective
Haloperidol-induced cognitive impairment
High doses of haloperidol impair performance
Impair task performance
Impaired cognitive function
Impaired reversal learning
Impaired task performance
Impaired task performance with haloperidol
Isolation rearing
None mentioned
PCP
PCP deficit
PCP exposure
PCP impairment
PCP induced cognitive deficit
PCP induced cognitive deficits
PCP induces cognitive impairment
PCP-induced cognitive deficit
PCP-induced cognitive deficits
PCP-induced deficit
PCP-induced psychosis
Psychosis
Psychotic symptoms
Rearing condition influence
Schizophrenia
Schizophrenia modeling
Schizophrenia symptoms
Social rearing sensitivity
Task performance impairment
Ziprasidone impairment

This study found that phencyclidine (PCP) induced a selective reversal learning deficit in rats, which was ameliorated following treatment with ziprasidone but not haloperidol. Isolation rearing did not influence performance of the test or the deficit produced by PCP. The study suggests that PCP may be a valid model for cognitive dysfunction associated with schizophrenia.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

19.

Ziprasidone suppresses olanzapine-induced increases in ingestive behaviour in the rat.

Author: KirkShona L, NeillJoanna C, JonesDeclan N C, ReynoldsGavin P

Atypical antipsychotic
Feeding behavior control
Food intake control
Food intake suppression
Improved antipsychotic treatment
Improved feeding behavior
Improved feeding behaviour
Improved metabolic health
Protection against drug-induced weight gain
Protection from drug-induced weight gain
Protective mechanism
Protective mechanism against drug-induced increases in food intake
Reduce food intake
Reduce olanzapine-induced weight gain
Reduce weight gain
Reduced drug-induced weight gain
Reduced food intake
Reduced weight gain
Reduces olanzapine-induced weight gain
Reduces weight gain
Suppresses food intake
Suppression of food intake
Weight Control
Weight control
Weight gain
Weight gain prevention
Weight gain reduction
Weight management
Ziprasidone
Ziprasidone effective
Ziprasidone efficacy
Ziprasidone for weight gain
Ziprasidone for weight gain prevention
Ziprasidone for weight management
Ziprasidone protection
Ziprasidone protects against weight gain
Ziprasidone reduces food intake
Ziprasidone reduces olanzapine weight gain
Ziprasidone reduces olanzapine-induced weight gain
Ziprasidone reduces weight
Ziprasidone reduces weight gain
Ziprasidone suppresses olanzapine-induced weight gain
Ziprasidone suppresses weight gain
Ziprasidone treatment
Ziprasidone use
Ziprasidone weight control
Ziprasidone weight gain
Ziprasidone weight gain prevention
Ziprasidone weight gain protection
Ziprasidone weight gain reduction
reduced food intake
ziprasidone for weight gain prevention
Atypical antipsychotic weight gain
Drug-induced weight gain
None reported
Olanzapine
Olanzapine increases food intake
Olanzapine induced weight gain
Olanzapine side effects
Olanzapine use
Olanzapine weight gain
Olanzapine-induced weight gain
Weight Gain
Weight gain

Ziprasidone, an atypical antipsychotic, reduces the acute effects of olanzapine on feeding behavior. This suggests that ziprasidone has a protective mechanism against drug-induced weight gain.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

20.

Differential effects of ziprasidone and haloperidol on immobilization stress-induced mRNA BDNF expression in the hippocampus and neocortex of rats.

Author: ParkSung Woo, LeeChan Hong, LeeJung Goo, LeeSun Jung, KimNa Ri, ChoiSang Mi, KimYoung Hoon

Ziprasidone may have neuroprotective effects by attenuating stress-induced decreases in brain-derived neurotrophic factor (BDNF) mRNA expression in the rat hippocampus and neocortex.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

22.

Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder.

Author: Swainston HarrisonTracy, ScottLesley J

Acute Agitation Control
Acute Agitation Treatment
Acute agitation
Acute agitation control
Acute agitation management
Acute agitation treatment
Agitation control
Control of acute agitation
Effective Schizophrenia Treatment
Effective agitation treatment
Effective for acute agitation
Effective for schizophrenia
Effective schizophrenia treatment
Effective treatment
Effective treatment for acute agitation
Effective treatment for schizophrenia
Effective treatment of schizophrenia
Fast-acting
Fast-acting IM
Fast-acting for acute agitation
Fast-acting for agitation
Fast-acting intramuscular
Fast-acting intramuscular formulation
Favorable tolerability
Favorable tolerability profile
Improved schizophrenia
Improved schizophrenia treatment
Low EPS
Low EPS Liability
Low EPS liability
Low Metabolic Complications
Low metabolic complications
Low propensity for metabolic complications
Low side effect profile
Low side effects
Low weight gain
Neutral Weight Gain
Neutral body weight
Neutral body weight gain
Neutral bodyweight
Neutral bodyweight gain
Neutral weight gain
Rapid agitation control
Reduced EPS Liability
Reduced EPS liability
Reduced agitation
Reduced extrapyramidal syndrome liability
Schizophrenia
Schizophrenia Treatment
Schizophrenia treatment
Tolerability
Treatment of acute agitation
Treatment of schizophrenia
Treats schizophrenia
Well tolerated
Ziprasidone
Ziprasidone effective schizophrenia
Ziprasidone schizophrenia treatment
Ziprasidone well-tolerated
EPS liability
Extrapyramidal syndrome
Metabolic complications
QT Prolongation
QT interval prolongation
QT prolongation
QTc Prolongation
QTc interval prolongation
QTc prolongation
Ziprasidone QTc prolongation
Ziprasidone QTc prolongation risk
Ziprasidone side effects

Ziprasidone is an atypical antipsychotic medication effective for treating schizophrenia and schizoaffective disorder. The oral formulation is suitable for both acute and chronic phases of these disorders, while the intramuscular formulation provides a fast-acting solution for controlling acute agitation. Ziprasidone generally has a favorable tolerability profile with a low risk of extrapyramidal side effects, neutral impact on body weight, and potential for minimal metabolic complications. However, clinicians should be aware of the drug's potential to prolong the QT interval.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

23.

Intramuscular ziprasidone treatment of acute psychotic agitation in elderly patients with schizophrenia.

Author: BarakYoram, MazehDoron, PlopskiIgor, BaruchYehuda

Acute psychosis treatment

Intramuscular ziprasidone treatment has been shown to be effective and well tolerated in reducing the symptoms of acute psychosis in adults. Further research is needed to evaluate its safety in elderly patients.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

24.

Intramuscular Midazolam, Olanzapine, Ziprasidone, or Haloperidol for Treating Acute Agitation in the Emergency Department.

Author: KleinLauren R, DriverBrian E, MinerJames R, MartelMarc L, HesselMichelle, CollinsJacob D, HortonGabriella B, FagerstromErik, SatpathyRajesh, ColeJon B

Effective sedation
Rapid onset
Hypotension
Hypoxemia
Intubation

Intramuscular midazolam achieved more effective sedation in agitated ED patients at 15 minutes than haloperidol, ziprasidone, and perhaps olanzapine. Olanzapine provided more effective sedation than haloperidol. No differences in adverse events were identified.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.

Language : English

25.

The utility of intramuscular ziprasidone in the management of acute psychotic agitation.

Author: MendelowitzAlan J

Acute agitation
Acute agitation control
Acute agitation treatment
Agitation Control
Agitation control
Agitation management
Agitation reduction
Agitation treatment
Atypical antipsychotic
Bipolar disorder treatment
Control acute agitation
Control agitation
Control of acute agitation
Control of acute psychosis
Control of agitation
Control symptoms
Controlled acute agitation
Controls agitation
Dementia treatment
Effective agitation treatment
Effective antipsychotic
Effective control of acute agitation
Effective for acute agitation
Effective for acute psychosis
Effective for agitation
Effective for schizophrenia
Effective for transition to oral therapy
Effective in controlling acute agitation
Effective treatment
Effective treatment of acute agitation
Fast acting
Faster acting antipsychotic
Faster action
Faster agitation control
IM ziprasidone
IM ziprasidone effective
IM ziprasidone effective for acute agitation
IM ziprasidone effective for agitation
IM ziprasidone efficacy
IM ziprasidone for agitation
IM ziprasidone for psychosis
IM ziprasidone tolerability
IM ziprasidone well-tolerated
Improve psychosis symptoms
Improved agitation
Improved agitation control
Improved agitation treatment
Improved efficacy
Improved psychosis
Improved psychosis control
Improved psychosis symptoms
Improved psychosis treatment
Improved psychotic symptoms
Improved symptom control
Improved symptom severity
Improved symptoms
Improved tolerability
Improvement in psychotic symptoms
Intramuscular injection
Intramuscular ziprasidone
Intramuscular ziprasidone efficacy
Less movement disorders
Low extrapyramidal symptoms
Low incidence of extrapyramidal symptoms
Low incidence of movement disorders
Low movement disorder
Low movement disorder risk
Low movement disorders
Low side effect profile
Low side effects
Lower incidence of movement disorders
Lower movement disorder
Lower movement disorder incidence
Lower movement disorder risk
Lower movement disorders
More effective than haloperidol
Movement disorder reduction
No excessive sedation
Psychiatric illnesses
Psychosis treatment
Rapid action
Rapid agitation control
Rapid onset
Rapid-acting
Rapid-acting IM
Reduce agitation
Reduced agitation
Reduced akathisia
Reduced discontinuation
Reduced dystonia
Reduced extrapyramidal symptoms
Reduced movement disorder
Reduced movement disorders
Reduced sedation
Reduced side effects
Reduces agitation
Reduces movement disorders
Schizophrenia treatment
Sequential IM/oral transition
Symptom Control
Symptom control
Symptom improvement
Tolerability
Tolerable transition
Treatment for agitation
Treatment of acute agitation
Treats acute agitation
Treats agitation
Well tolerated
Well-tolerated
Ziprasidone
Ziprasidone IM for agitation
Ziprasidone IM for psychosis
Ziprasidone IM transition to oral
Ziprasidone agitation control
Ziprasidone agitation treatment
Ziprasidone control of agitation
Ziprasidone controls agitation
Ziprasidone effective
Ziprasidone effective for agitation
Ziprasidone efficacy
Ziprasidone for acute agitation
Ziprasidone for agitation
Ziprasidone for psychosis
Ziprasidone for psychosis agitation treatment
Ziprasidone i.m.
Ziprasidone less movement disorders
Ziprasidone more effective than haloperidol
Ziprasidone movement disorder reduction
Ziprasidone safe
Ziprasidone safer than haloperidol
Ziprasidone safety
Ziprasidone superior to haloperidol
Ziprasidone tolerability
Ziprasidone tolerated
Ziprasidone treatment
Ziprasidone well tolerated
Ziprasidone well-tolerated
lower incidence of movement disorders
reduced agitation
symptom control
ziprasidone for acute agitation
ziprasidone for schizophrenia
Acute agitation
Adverse events
Agitation
Agitation difficult to manage
Agitation in psychiatric illnesses
Akathisia
Bipolar disorder
Dementia
Discontinuation
Discontinuation due to adverse events
Discontinuation due to side effects
Discontinuation events
Dystonia
Excessive sedation
Extrapyramidal symptoms
High discontinuation
Movement Disorder
Movement disorder
Movement disorder risk
Movement disorder side effects
Movement disorders
None reported
Psychiatric illnesses
Schizophrenia
Sedation
Similar discontinuations to haloperidol
Ziprasidone movement disorders
discontinuation due to adverse events

Intramuscular ziprasidone is a safe and effective treatment for acute agitation in patients with various psychiatric illnesses. It is associated with a lower incidence of movement disorders compared to haloperidol.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

26.

Lithium intoxication associated with intramuscular ziprasidone in schizoaffective patients.

Author: MiodownikChanoch, HausmannMichael, FrolovaKatherina, LernerVladimir

Mood disorder treatment
Lithium intoxication

This report describes two schizoaffective patients who developed lithium intoxication after intramuscular ziprasidone treatment. The authors suggest that the rapid increase in ziprasidone serum levels after parenteral application may have affected lithium excretion, leading to lithium intoxication.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

27.

Pharmacokinetics and therapeutics of acute intramuscular ziprasidone.

Author: PreskornSheldon H

Acute agitation control
Acute psychosis
Acute psychosis treatment
Agitation control
Agitation management
Agitation reduction
Agitation treatment
Atypical antipsychotic
Cardiovascular safety
Control of acute agitation
Effective agitation treatment
Effective for agitation
Effective treatment
Fast acting
Fast acting antipsychotic
Fast action
Fast onset of action
Faster Action
Faster acting
Faster acting antipsychotic
Faster action
Faster action onset
Faster agitation control
Faster onset
Faster onset of action
Good tolerability
IM ziprasidone
IM ziprasidone effective
IM ziprasidone effective for agitation
IM ziprasidone efficacy
IM ziprasidone for agitation
IM ziprasidone for psychosis
IM ziprasidone rapid
IM ziprasidone rapid absorption
IM ziprasidone tolerability
IM ziprasidone well-tolerated
Improved Safety
Improved agitation
Improved psychosis
Improved psychosis control
Improved psychosis management
Improved psychosis symptoms
Improved psychosis treatment
Improved psychotic symptoms
Improved symptom control
Improved symptom severity
Improved symptoms
Improved tolerability
Intramuscular injection
Intramuscular ziprasidone
Intramuscular ziprasidone efficacy
Intramuscular ziprasidone for agitation
Intramuscular ziprasidone pharmacokinetics
Intramuscular ziprasidone rapidly effective
Intramuscular ziprasidone safe
Intramuscular ziprasidone safety
Intramuscular ziprasidone tolerability
Intramuscular ziprasidone well tolerated
Less movement disorders
Low movement disorder risk
Low movement disorders
Low side effect profile
Low side effects
Lower burden of movement disorders
Lower incidence of movement disorders
Lower movement disorders
Lower risk of movement disorders
Psychosis management
Psychosis treatment
Rapid absorption
Rapid absorption of ziprasidone
Rapid action
Rapid agitation control
Rapid agitation reduction
Rapid onset
Rapid onset of action
Rapid symptom relief
Reduce agitation
Reduced agitation
Reduced extrapyramidal symptoms
Reduced movement disorder
Reduced movement disorders
Reduced side effects
Safe for elderly
Schizophrenia treatment
Symptom control
Tolerability
Tolerable
Treatment of acute psychosis
Treats acute psychosis
Treats agitation
Well characterized safety
Well characterized safety profile
Well characterized tolerability and safety
Well tolerated
Well-characterized cardiovascular safety
Well-characterized tolerability
Well-tolerated
Ziprasidone
Ziprasidone IM faster action
Ziprasidone IM for acute agitation
Ziprasidone IM well-tolerated
Ziprasidone absorption
Ziprasidone agitation control
Ziprasidone agitation treatment
Ziprasidone bioavailability
Ziprasidone effective
Ziprasidone effective for agitation
Ziprasidone effective for psychosis
Ziprasidone efficacy
Ziprasidone for acute psychosis
Ziprasidone for acute psychosis agitation
Ziprasidone for agitation
Ziprasidone for psychosis
Ziprasidone for psychosis agitation treatment
Ziprasidone i.m.
Ziprasidone i.m. effective
Ziprasidone i.m. safe
Ziprasidone i.m. tolerated
Ziprasidone lower movement disorder risk
Ziprasidone pharmacokinetics
Ziprasidone rapid action
Ziprasidone safer than conventional antipsychotics
Ziprasidone safety
Ziprasidone tolerability
Ziprasidone treatment
Ziprasidone well tolerated
Ziprasidone well-tolerated
rapid onset of action
well tolerated
ziprasidone for acute psychosis
ziprasidone for agitation
Acute agitation
Acute dystonia
Acute psychosis
Agitation
Agitation distress
Agitation hazardous
Cardiovascular safety
Conventional antipsychotic side effects
Drug accumulation
Movement Disorder
Movement disorder
Movement disorder adverse events
Movement disorder related adverse events
Movement disorder risk
Movement disorder side effects
Movement disorder-related adverse events
Movement disorders
None reported
Possible cardiovascular effects
movement disorder-related adverse events

Intramuscular ziprasidone is a safe and effective treatment for acute agitation in patients with psychosis. It offers rapid absorption, a faster onset of action, and fewer movement disorder-related adverse events compared to conventional antipsychotics.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

28.

P wave and QT changes among inpatients with schizophrenia after parenteral ziprasidone administration.

Author: EmulMurat, DalkiranMihriban, CoskunOrhan, YavuzRuhi, TosunMusa, DuranAlaattin, UgurMufit, KelesIbrahim

Intramuscular ziprasidone may increase proneness to atrial fibrillation in drug-free inpatients with schizophrenia.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

29.

Intramuscular ziprasidone versus haloperidol for managing agitation in Chinese patients with schizophrenia.

Author: ZhangHongyan, WangGang, ZhaoJingping, XieShiping, XuXiufeng, ShiJianguo, DengHehuang, LiKeqing, GaoChengge, WangXiaoping, VanderburgDouglas, PanSharon, TangHaiyun, ShuLiang, KarayalOnur N

This study compared the efficacy and tolerability of IM ziprasidone versus IM haloperidol for managing agitation in Chinese subjects with schizophrenia, finding comparable efficacy but significantly better tolerability for ziprasidone, with a lower incidence of extrapyramidal symptoms.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.